Previous 10 | Next 10 |
home / stock / teva / teva articles
Teva Pharmaceutical Industries Ltd (NYSE: TEVA) reported Q3 sales of $3.85 billion, beating the consensus of $3.72 billion. The 7% Y/Y in...
Stock futures indicate a subdued opening on Wednesday after several consecutive gains in major averages. Traders are eagerly awaiting Federal Reser...
Alkermes PLC (NASDAQ: ALKS) reported Q3 FY23 adjusted EPS of $0.64 compared to $0.02 a year ago, beating the consensus of $0.43. The comp...
As Israel ramps up its armed forces and a regional war with Hamas enters its fourth day, the country is considering forming an emergency government...
Teva Pharmaceutical Industries Ltd (NYSE: TEVA) shares are trading lower by 2.7% to $9.17 Monday morning amid conflict in the company's ho...
Benzinga AI Powerhouse: Palantir And PwC Team Up To Accelerate Data-Driven Operations Palantir Technologies Inc (NYSE: PLTR) is expanding its...
Sanofi SA (NASDAQ: SNY) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA) have collaborated to co-develop and co-commercializ...
Editor's note: This article has been updated with more details from the Access to Medicine Foundation's study. Despite significa...
Benzinga Alibaba's Logistics Arm Cainiao Files For Hong Kong IPO Alibaba Group Holding Limited (NYSE: BABA) stock is trading higher Wedne...
News, Short Squeeze, Breakout and More Instantly...
Teva Pharmaceutical Industries Limited American Depositary Shares Company Name:
TEVA Stock Symbol:
NYSE Market:
Teva Pharmaceutical Industries Limited American Depositary Shares Website:
2024-07-10 08:00:08 ET Ashwani Verma from UBS issued a price target of $24.00 for TEVA on 2024-07-10 07:20:00. The adjusted price target was set to $24.00. At the time of the announcement, TEVA was trading at $15.81. The overall price target consensus is at $15.00 with h...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial results on Wednesday, July 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8...
4th interim analysis of PEARL real world migraine prevention study presented at 10th European Association of Neurology (EAN) congress in Helsinki New sub-analysis of PEARL data highlights potential negative impact of treatment pauses on patient outcomes 1 Sub-analysis explorin...